PARP

poly ADP ribose polymerase

PARP is a family of proteins involved in a number of cellular processes involving mainly DNA repair and programmed cell death. The PARP family comprises 17 members. They have all very different structures and functions in the cell. PARP1, PARP2, VPARP (PARP4), Tankyrase-1 and -2 (PARP-5a or TNKS, and PARP-5b or TNKS2) have a confirmed PARP activity. Others include PARP3, PARP6, TIPARP (or PARP7), PARP8, PARP9, PARP10, PARP11, PARP12, PARP14, PARP15, and PARP16. PARP is found in the cell's nucleus. The main role is to detect and signal single-strand DNA breaks (SSB) to the enzymatic machinery involved in the SSB repair.

PARP Inhibitors, Activators, Agonists & Inducers

(8R,9S)-Talazoparib

((8R,9S)-BMN-673; (8R,9S)-LT-673)

Cat. No.: HY-16106A

(8R,9S)-Talazoparib ((8R,9S)-BMN-673) is an enantiomer of Talazoparib. (8R,9S)-Talazoparib is an **PARP1** inhibitor, with an IC_{50} of 144 nM.



Purity: 98.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

1,5-Isoquinolinediol

Cat. No.: HY-W015422

1,5-Isoquinolinediol is a potent **PARP** inhibitor, with an IC_{50} of 0.18-0.37 μM. 1,5-Isoquinolinediol attenuates diabetes-induced NADPH oxidase-derived oxidative stress in retina.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

2-Methylquinazolin-4-ol

Cat. No.: HY-W051513

2-Methylquinazolin-4-ol is a potent competitive **poly(ADP-ribose) synthetase** inhibitor, with a K_i of 1.1 μM. 2-Methylquinazolin-4-ol mammalian **aspartate transcarbamylase (ATCase)** inhibitor, with 0.20 mM.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 500 mg, 1 g

3-Aminobenzamide

(PARP-IN-1)

Cat. No.: HY-12022

3-Aminobenzamide (PARP-IN-1) is a potent inhibitor of **PARP** with IC_{50} of appr
50 nM in CHO cells, and acts as a mediator of oxidant-induced myocyte dysfunction during reperfusion.



Purity: 99.92%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 200 mg, 500 mg

3-Methoxybenzamide

(3-MBA)

Cat. No.: HY-121497

3-Methoxybenzamide (3-MBA), an inhibitor of **ADP-ribosyltransferase (ADPRTs)** and **PARP**, inhibits cell division in Bacillus subtilis, leading to filamentation and eventually lysis of cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4'-Methoxychalcone

Cat. No.: HY-128400

4'-Methoxychalcone regulates adipocyte differentiation through **PPARγ** activation. 4'-Methoxychalcone modulates the expression and secretion of various adipokines in adipose tissue that are involved in insulin sensitivity.



Purity: 99.44%
Clinical Data:
Size: 25 mg, 50 mg, 100 mg

4-Aminonaphthalimide

Cat. No.: HY-15276

4-Aminonaphthalimide is a potent **PARP** inhibitor and potentiates the cytotoxicity of γ-radiation in cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5,7-Dihydroxychromone

Cat. No.: HY-N1970

5,7-Dihydroxychromone, the extract of Cudrania tricuspidata, activates **Nrf2/ARE** signal and exerts neuroprotective effects against 6-hydroxydopamine (6-OHDA)-induced oxidative stress and **apoptosis**.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

5,7,4'-Trimethoxyflavone

Cat. No.: HY-N6818

5,7,4'-Trimethoxyflavone is isolated from Kaempferia parviflora (KP) that is a famous medicinal plant from Thailand.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

A-966492

Cat. No.: HY-10614

A-966492 is a novel and potent inhibitor of **PARP1** and <
b>PARP2 with K_i of
1 nM and 1.5 nM, respectively.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

AG14361

Cat. No.: HY-12032

AG14361 is a potent **PARP-1** inhibitor, with a K_i of < 5 nM, and in permeabilized SW620 and intact SW620 cells, the IC_{50}s are 29 nM and 14 nM, respectively.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Amelparib

(JPI-289)

Cat. No.: HY-116218

Amelparib is a potent, orally active, and water-soluble inhibitor of **PARP-1**. Amelparib inhibits PARP-1 activity (IC_{50} =18.5 nmol/L) and cellular PAR formation (IC_{50} =10.7 nmol/L) in the nanomolar range. Amelparib is a potential neuroprotective agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anticancer agent 43

Cat. No.: HY-146548

Anticancer Agent 43 is a potent anticancer agent. Anticancer Agent 43 induces **apoptosis** by caspase 3, PARP1, and Bax dependent mechanisms. Anticancer Agent 43 induces DNA damage.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ART-IN-1

Cat. No.: HY-143338

ART-IN-1 (compound 7) is a selective **PARP** inhibitor with IC_{50}s of 19, 22, 2.4, >100, 1.1 μM for PARP2, TNKS2, PARP10, PARP14, PARP15, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZ3391

Cat. No.: HY-144874

AZ3391 is a potent inhibitor of **PARP**. AZ3391 is a quinoxaline derivative. PARP family of enzymes play an important role in a number of cellular processes, such as replication, recombination, chromatin remodeling, and DNA damage repair.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZ6102

Cat. No.: HY-12975

AZ6102 is a potent dual **TNKS1** and **TNKS2** inhibitor, with IC_{50}s of 3 nM and 1 nM, respectively, and alao has 100-fold selectivity against other PARP family enzymes, with IC_{50}s of 2.0 μM, 0.5 μM, and >3 μM, for PARP1, PARP2, and PARP6, respectively.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZ9482

Cat. No.: HY-119653

AZ9482 is a triple **PARP1/2/6** inhibitor, with IC_{50} values of 1 nM, 1 nM and 640 nM for PARP1, PARP2 and PARP6, respectively.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

AZD-2461

Cat. No.: HY-13536

AZD-2461 is a potent **PARP** inhibitor, with IC_{50}s of 5 nM, 2 nM and 200 nM for PARP1, PARP2 and PARP3, respectively.



Purity: 99.88%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD5305

Cat. No.: HY-132167

AZD5305 is a potent, selective and oral active **PARP** inhibitor. AZD5305 is potent and efficacious in animal xenografts and PDX models.



Purity: 99.56%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Benzamide

(NSC-3114; Benzenecarboxamide; Phenylamide)

Cat. No.: HY-Z0283

Benzamide inhibits **poly(ADP-ribose) polymerase (PARP)**.



Purity: 98.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Benzamide-15N

(NSC-3114-15N; Benzenecarboxamide-15N; Phenylamide-15N)

Cat. No.: HY-Z0283S

Benzamide-15N (NSC-3114-15N) is a 15N-labeled Benzamide. Benzamide inhibits **poly(ADP-ribose) polymerase (PARP)**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 500 mg, 1 g

BGP-15

Cat. No.: HY-100828

BGP-15 is a **PARP** inhibitor, with an IC_{50} and a K_i of 120 and 57 μM, respectively.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

BR102375

Cat. No.: HY-128344

BR102375 is a non-TZD peroxisome proliferator-activated receptor γ (**PPAR γ**) full agonist for the treatment of type 2 diabetes, reveals EC_{50} value of 0.28 μM and A_{max} ratio of 98%.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRCA1-IN-1

Cat. No.: HY-100863

BRCA1-IN-1 is a novel small-molecule-like **BRCA1** inhibitor with IC_{50} and K_i of 0.53 μM and 0.71 μM, respecrively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRCA1-IN-2

Cat. No.: HY-100862

BRCA1-IN-2 (compound 15) is a cell-permeable protein-protein interaction (PPI) inhibitor for **BRCA1** with an IC_{50} of 0.31 μM and a K_d of 0.3 μM, which shows antitumor activities via the disruption of $BRCT)_2$/protein interactions.



Purity: 98.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

BYK204165

Cat. No.: HY-108632

BYK204165 is a potent and selective **PARP1** inhibitor. BYK204165 inhibits cell-free recombinant human PARP-1 (**hPARP-1**) with a pIC_{50} of 7.35 (pK_i=7.05), and murine PARP-2 (**mPARP-2**) with a pIC_{50} of 5.38, respectively. BYK204165 displays 100-fold selectivity for PARP-1.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CEP-9722

Cat. No.: HY-105303

CEP-9722, the prodrug of CEP-8983, is a selective and orally active **PARP-1** and **PARP-2** inhibitor with IC_{50}s of 20 nM and 6 nM, respectively. CEP-9722 has anticancer effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dehydrocorydaline

(13-Methylpalmatine)

Cat. No.: HY-N0674

Dehydrocorydaline (13-Methylpalmatine) is an alkaloid that regulates protein expression of **Bax**, **Bcl-2**; activates **caspase-7**, **caspase-8**, and inactivates **PARP**. Dehydrocorydaline elevates **p38 MAPK** activation. Anti-inflammatory and anti-cancer activities.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Dehydrocorydaline chloride

(13-Methylpalmatine chloride)

Cat. No.: HY-N0674A

Dehydrocorydaline chloride (13-Methylpalmatine chloride) is an alkaloid that regulates protein expression of **Bax**, **Bcl-2**; activates **caspase-7**, **caspase-8**, and inactivates **PARP**. Dehydrocorydaline chloride elevates **p38 MAPK** activation.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Dehydrocorydaline nitrate

(13-Methylpalmatine nitrate)

Cat. No.: HY-N4238

Dehydrocorydaline nitrate (13-Methylpalmatine nitrate) is an alkaloid. Dehydrocorydaline regulates protein expression of **Bax**, **Bcl-2**; activates **caspase-7**, **caspase-8**, and inactivates **PARP**. Dehydrocorydaline nitrate elevates **p38 MAPK** activation.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

DP-C-4

Cat. No.: HY-141481

DP-C-4 is a **Cereblon**-based dual **PROTAC** for simultaneous degradation of **EGFR** and **PARP**.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

DPQ

Cat. No.: HY-114869

DPQ is a potent **PARP-1** inhibitor. DPQ can reduce the N-methyl-d-aspartate (NMDA)-induced PARP activation, restoring ATP to near control levels and significantly attenuating neuronal injury in the severe NMDA exposure model. DPQ can be used for researching neuroprotection.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DR2313

Cat. No.: HY-105692

DR2313 is a potent, selective, competitive and brain-penetrant inhibitor of **poly(ADP-ribose) polymerase (PARP)**, with IC_{50}s of 0.20 μM and 0.24 μM for **PARP-1** and **PARP-2**, respectively. DR2313 exhibits neuroprotective effects on ischemic injuries in vitro and in vivo.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

E7016

(GPI 21016)

Cat. No.: HY-13540

E7016 (GPI 21016) is an orally available **PARP** inhibitor. E7016 can enhance tumor cell radiosensitivity in vitro and in vivo through the inhibition of DNA repair. E7016 acts as a potential anticancer agent.



Purity: 98.46%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

E7449

Cat. No.: HY-12418

E7449 is a potent **PARP1** and **PARP2** inhibitor and also inhibits **TNKS1** and **TNKS2**, with IC_{50}s of 2.0, 1.0, 50 and 50 nM for PARP1, PARP2, TNKS1 and TNKS2, respectively, using ^{32}P-NAD$^+$ as substrate.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EB-47

Cat. No.: HY-15046

EB-47, a potent and selective **PARP-1/ARTD-1** inhibitor with an IC_{50} value of 45 nM, shows modest potency against ARTD5 with an IC_{50} value of 410 nM. EB-47 mimics the substrate NAD$^+$ and extends from the nicotinamide to the adenosine subsite.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

EB-47 dihydrochloride

Cat. No.: HY-108631

EB-47 dihydrochloride, a potent and selective **PARP-1/ARTD-1** inhibitor with an IC_{50} value of 45 nM, shows modest potency against ARTD5 with an IC_{50} value of 410 nM. EB-47 mimics the substrate NAD$^+$ and extends from the nicotinamide to the adenosine subsite.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fluorescein-NAD+

Cat. No.: HY-131009

Fluorescein-NAD+ is an alternative to radiolabeled NAD and a **substrate for ADP-ribosylation**. Fluorescein-NAD+ can be used in PARP assays by fluorescence microscopy. Extinction Coefficient: 262 nm.



Purity: >98%
Clinical Data: No Development Reported
Size: 81 μg

Fluzoparib

(SHR3162; Fuzuloparib)

Cat. No.: HY-114778

Fluzoparib (SHR3162) is a potent and orally active **PARP1** inhibitor (IC_{50}=1.46±0.72 nM, a cellfree enzymatic assay) with superior antitumor activity.



Purity: 99.85%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fucosterol

Cat. No.: HY-N4103

Fucosterol is a sterol isolated from algae, seaweed or diatoms. Fucosterol exhibits various biological activities, including antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

G007-LK

Cat. No.: HY-12438

G007-LK is a potent and selective inhibitor of **TNKS1** and **TNKS2**, with IC_{50}s of 46 nM and 25 nM, respectively.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

G244-LM

Cat. No.: HY-117705

G244-LM is a potent and specific inhibitor of **tankyrase 1/2** that inhibits **Wnt** signaling.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GeA-69

Cat. No.: HY-108708

GeA-69 is a selective, allosteric inhibitor of **poly-adenosine-diphosphate-ribose polymerase 14 (PARP14)** targeting macrodomain 2, with a K_d of 2.1 μM.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Iniparib

(BSI-201; NSC-746045; IND-71677)

Cat. No.: HY-12015

Iniparib (BSI-201) is an irreversible inhibitor of **PARP1**, used in the research of triple negative breast cancer.



Purity: 99.87%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

INO-1001

Cat. No.: HY-15045

INO-1001 is a potent and selective **poly (ADP-ribose) polymerase (PARP)** inhibitor. INO-1001 is a potent enhancer of radiation sensitivity and enhances radiation-induced cell killing by interfering with DNA repair mechanisms, resulting in necrotic cell death.



Purity: 98.19%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

iRucaparib-AP6

Cat. No.: HY-130644

iRucaparib-AP6 is a highly efficient and specific **PARP1** degrader based on Rucaparib by using the PROTAC approach. iRucaparib-AP6, a non-trapping PARP1 degrader, blocks both the catalytic activity and scaffolding effects of PARP1.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

JW 55

Cat. No.: HY-13968

JW 55 is a potent and selective **β-catenin** signaling pathway inhibitor, which functions via inhibition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2). JW 55 decreases auto-PARsylation of TNKS1/2 in vitro with IC_{50}s of 1.9 μM and 830 nM respectively.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

K-756

Cat. No.: HY-U00422

K-756 is a direct and selective **tankyrase** (**TNKS**) inhibitor, which inhibits the ADP-ribosylation activity of **TNKS1** and **TNKS2** with IC_{50}s of 31 and 36 nM, respectively.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

KCL-440

Cat. No.: HY-15050

KCL-440 is a CNS-penetrated **PARP** inhibitor, with an IC_{50} of 68 nM. KCL-440 has strong inhibition of PARP-1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KSQ-4279

(USP1-IN-1)

Cat. No.: HY-145471

KSQ-4279 (USP1-IN-1, Formula I) is a **USP1** and **PARP** inhibitor (extracted from patent WO2021163530).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

ME0328

Cat. No.: HY-100225

ME0328 is a potent and selective **ARTD3/PARP3** inhibitor with an IC_{50} of 0.89±0.28 μM.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Mefuparib hydrochloride

(MPH)

Cat. No.: HY-122661

Mefuparib hydrochloride (MPH) is an orally active, substrate-competitive and selective **PARP1/2** inhibitor with IC_{50}s of 3.2 nM and 1.9 nM, respectively. Mefuparib hydrochloride induces **apoptosis** and possesses prominent anticancer activity in vitro and in vivo.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

MN-64

Cat. No.: HY-19351

MN-64 is a potent **tankyrase 1** inhibitor, with IC_{50}s of 6 nM, 72 nM, 19.1 μM, and 39.4 μM for **TNKS1**, TNKS2, ARTD1 and ARTD2, respectively.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

N-Descyclopropanecarbaldehyde Olaparib

Cat. No.: HY-75706

N-Descyclopropanecarbaldehyde Olaparib is an analogue of Olaparib containing DOTA moiety. N-Descyclopropanecarbaldehyde Olaparib is a CRBN-based **ligand** for synthesizing novel dual **EGFR** and **PARP** PROTAC, DP-C-4.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 250 mg

NCT-TFP

Cat. No.: HY-D1107

NCT-TFP is PARP probe used to identifying Poly(ADP-ribose) polymerases (PARP) inhibitors (extracted from patent US20190331688A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nesuparib

Cat. No.: HY-145584

Nesuparib is a potent inhibitor of **PARP**. Nesuparib is useful for the research of neuropathic pain, neurodegenerative disease, and cardiovascular disease (extracted from patent WO2016200101A2).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Niraparib

(MK-4827)

Cat. No.: HY-10619

Niraparib (MK-4827) is a highly potent and orally bioavailable **PARP1** and **PARP2** inhibitor with IC_{50}s of 3.8 and 2.1 nM, respectively. Niraparib leads to inhibition of repair of DNA damage, activates **apoptosis** and shows anti-tumor activity.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Niraparib (R-enantiomer)

(MK 4827 (R-enantiomer))

Cat. No.: HY-10619D

Niraparib R-enantiomer (MK-4827 R-enantiomer) is an excellent **PARP1** inhibitor with IC_{50} of 2.4 nM.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Niraparib hydrochloride

(MK-4827 hydrochloride)

Cat. No.: HY-10619A

Niraparib hydrochloride (MK-4827 hydrochloride) is a highly potent and orally bioavailable **PARP1** and **PARP2** inhibitor with IC_{50}s of 3.8 and 2.1 nM, respectively. Niraparib hydrochloride leads to inhibition of repair of DNA damage, activates **apoptosis** and shows anti-tumor activity.



Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Niraparib tosylate

(MK-4827 tosylate)

Cat. No.: HY-10619B

Niraparib tosylate (MK-4827 tosylate) is a highly potent and orally bioavailable **PARP1** and **PARP2** inhibitor with an IC_{50} of 3.8 and 2.1 nM, respectively. Niraparib tosylate leads to inhibition of repair of DNA damage, activates **apoptosis** and shows anti-tumor activity.



Purity: 99.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NMS-P118

Cat. No.: HY-18954

NMS-P118 is a potent, orally available, and highly selective **PARP-1** Inhibitor for cancer therapy.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NMS-P515

Cat. No.: HY-128599

NMS-P515 is a potent, orally active and stereospecific **PARP-1** inhibitor, with a K_d of 16 nM and an IC_{50} of 27 nM (in Hela cells). Anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NU1025

Cat. No.: HY-15044

NU1025 is a potent **PARP** inhibitor with an IC_{50} of 400 nM and a K_i of 48 nM. NU1025 potentiates the cytotoxicity of ionizing radiation and anticancer drugs. NU1025 has anti-cancer and neuroprotective activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Nudifloramide

(2PY)

Cat. No.: HY-113432

Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits **poly(ADP-ribose) polymerase (PARP-1)** activity in vitro.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Nudifloramide-d3

Cat. No.: HY-113432S

Nudifloramide-d3 (2PY-d3) is the deuterium labeled Nudifloramide. Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits **poly(ADP-ribose) polymerase (PARP-1)** activity in vitro.



Purity: >98%
Clinical Data:
Size: 2.5 mg, 25 mg

NVP-TNKS656

(TNKS656)

Cat. No.: HY-13990

NVP-TNKS656 is a highly potent, selective, and orally active **TNKS2** inhibitor with IC_{50} of 6 nM, and is > 300 fold selectivity against **PARP1** and **PARP2**.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Olaparib

(AZD2281; KU0059436)

Cat. No.: HY-10162

Olaparib (AZD2281; KU0059436) is a potent and orally active **PARP** inhibitor with IC_{50}s of 5 and 1 nM for **PARP1** and **PARP2**, respectively. Olaparib is an **autophagy** and **mitophagy** activator.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Olaparib-d4-1

(AZD2281-d4-1; KU0059436-d4-1)

Cat. No.: HY-10162S3

Olaparib-d4-1 (AZD2281-d4-1) is the deuterium labeled Olaparib. Olaparib (AZD2281; KU0059436) is a potent and orally active **PARP** inhibitor with IC_{50}s of 5 and 1 nM for **PARP1** and **PARP2**, respectively. Olaparib is an **autophagy** and **mitophagy** activator.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Olaparib-d5

(AZD2281-d5; KU0059436-d5)

Cat. No.: HY-10162S

Olaparib D5 (AZD2281 D5) is a deuterium labeled Olaparib. Olaparib is a potent and oral **PARP** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Olaparib-d8

(AZD2281-d8; KU0059436-d8)

Cat. No.: HY-10162S1

Olaparib D8 (AZD2281 D8) is the deuterium labeled Olaparib (AZD2281). Olaparib is a potent and orally active **PARP** inhibitor with IC_{50}s of 5 and 1 nM for **PARP1** and **PARP2**, respectively. Olaparib is an **autophagy** and **mitophagy** activator.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OM-153

Cat. No.: HY-145267

OM-153 is a potent **tankyrase** inhibitor with IC_{50}s of 13 and 2 nM for tankyrase 1 and tankyrase 2, respectively. OM-153 shows inhibition of WNT/β-catenin signaling and proliferation in COLO 320DM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OM-1700

Cat. No.: HY-145266

OM-1700 is a potent **tankyrase** inhibitor with IC_{50}s of 127 and 14 nM for tankyrase 1 and tankyrase 2, respectively. OM-1700 reduces cell growth in the colon cancer cell line COLO 320DM (GI_{50}=650 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OUL35

(NSC39047)

Cat. No.: HY-123512

OUL35 (NSC39047) is a potent and selective inhibitor of **ARTD10 (PARP-10)**, with an IC_{50} of 329 nM.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Pamiparib

(BGB-290)

Cat. No.: HY-104044

Pamiparib (BGB-290) is an orally active, potent, highly selective **PARP** inhibitor, with IC_{50} values of 0.9 nM and 0.5 nM for **PARP1** and **PARP2**, respectively.



Purity: 99.97%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Paris saponin VII

(Chonglou Saponin VII)

Cat. No.: HY-N3584

Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii Maxim. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with **Akt/MAPK** and the inhibition of **P-gp**.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PARP-1-IN-1

Cat. No.: HY-144642

PARP-1-IN-1 is a high selective and orally active **PARP-1** inhibitor (IC_{50}=0.96 nM). PARP-1-IN-1 has well tolerance and remarkable single dose activity in the MDA-MB-436 xenotransplantation model.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PARP-1/2-IN-1

Cat. No.: HY-145328

PARP-1/2-IN-1 is a potent PARP-1/2 inhibitor with IC_{50} of 0.51 nM and 23.11 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PARP-2-IN-1

Cat. No.: HY-102035

PARP-2-IN-1 is a potent and selective **PARP-2** inhibitor with an IC_{50} of 11.5 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PARP/EZH2-IN-1

Cat. No.: HY-132885

PARP/EZH2-IN-1 is a first-in-class dual **PARP** (IC_{50} 6.87 nM) and **EZH2** (IC_{50} 36.51 nM) inhibitor for triple-negative breast cancer with wild-type BRCA.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PARP/PI3K-IN-1

Cat. No.: HY-133124

PARP/PI3K-IN-1 (compound 15) is a potent **PARP/PI3K** inhibitor with pIC_{50} values of 8.22, 8.44, 8.25, 6.54, 8.13, 6.08 for PARP-1, PARP-2, PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ, respectively. PARP/PI3K-IN-1 is a highly effective anticancer compound targeted against a wide range of oncologic diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PARP1-IN-5

Cat. No.: HY-132297

PARP1-IN-5 is a low toxicity, orally active, potent and selective **PARP-1** inhibitor (IC_{50} =14.7 nM). PARP1-IN-5 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PARP1-IN-5 dihydrochloride

Cat. No.: HY-132297A

PARP1-IN-5 dihydrochloride is a low toxicity, orally active, potent and selective **PARP-1** inhibitor (IC_{50} =14.7 nM). PARP1-IN-5 dihydrochloride can be used for the research of cancer.



Purity: 97.21%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PARP1-IN-6

Cat. No.: HY-139879

PARP1-IN-6 is a dual **tubulin/PARP-1** inhibitor with IC_{50} values of 0.94 and 0.48 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PARP1-IN-7

Cat. No.: HY-142657

PARP1-IN-7 is an inhibitor of **poly(ADP-ribose) polymerase-1 (PARP1)** as an anticancer agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PARP1/2/TNKS1/2-IN-1

Cat. No.: HY-146336

PARP1/2/TNKS1/2-IN-1 (Compound I-9) is a dual **PARP-1**, **PARP-2**, **TNKS1** and **TNKS2** inhibitor with IC_{50} values of 0.25 nM, 1.2 nM, 13.5 nM and 4.15 nM against PARP-1, PARP-2, TNKS1 and TNKS2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PARP1/BRD4-IN-1

Cat. No.: HY-144338

PARP1/BRD4-IN-1 is a potent and high selective **PARP1/BRD4** inhibitor (IC_{50}s of 49 and 202 nM in PARP1 and BRD4, respectively). PARP1/BRD4-IN-1 represses the expression and activity of PARP1 and BRD4 to synergistically inhibit the malignant growth of pancreatic cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PARP10/15-IN-1

Cat. No.: HY-143398

PARP10/15-IN-1 (compound 8l) is a potent inhibitor of dual inhibitor of **PARP10** and **PARP15**, with IC_{50}s of 160 nM and 370 nM, respectively. PARP10/15-IN-1 can be used for cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PARP10/15-IN-2

Cat. No.: HY-146501

PARP10/15-IN-2 (Compound 8h) is a potent **PARP10** and **PARP15** dual inhibitor with IC_{50} values of 0.15 μM and 0.37 μM against PARP10 and PARP15, respectively. PARP10/15-IN-2 is able to enter cells and rescue cells from **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PARP10/15-IN-3

Cat. No.: HY-146502

PARP10/15-IN-3 (Compound 8a) is a potent **PARP10** and **PARP15** dual inhibitor with IC_{50} values of 0.14 μM and 0.40 μM against PARP10 and PARP15, respectively. PARP10/15-IN-3 is able to enter cells and rescue cells from **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PARP14 inhibitor H10

Cat. No.: HY-117889

PARP14 inhibitor H10, compound H 10, is a selective inhibitor against **PARP14** (IC_{50}=490 nM), over other PARPs (≈24 fold over PARP1). PARP14 inhibitor H10 induces caspase-3/7-mediated cell **apoptosis**.



Purity: 98.16%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

PJ34

Cat. No.: HY-13688A

PJ34 is a potent specific inhibitor of **PARPl/2** with IC_{50} of 110 nM and 86 nM, respectively.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PJ34 hydrochloride

Cat. No.: HY-13688

PJ34 hydrochloride is an inhibitor of **PARP1/2** with IC_{50} of 110 nM and 86 nM, respectively.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PROTAC PARP1 degrader

Cat. No.: HY-114324

PROTAC PARP1 degrader is a **PARP1** degrader based on **MDM2** E3 ligand. It induces significant PARP1 cleavage and programmed cell death. PROTAC PARP1 degrader at 10 μM at 24 h inhibits MDA-MB-231 cell line with an IC_{50} of 6.12 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

RBN-2397

Cat. No.: HY-136174

RBN-2397 is a potent, accross species and orally active NAD^+ competitive inhibitor of **PARP7** (IC_{50}<3 nM). RBN-2397 selectively binds to PARP7 (K_d=0.001 μM) and restores IFN signaling. RBN-2397 has the potential for the study of advanced or metastatic solid tumors.



Purity: 99.45%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RBN012759

Cat. No.: HY-136979

RBN012759 is a potent, selective and orally active inhibitor of **PARP14**, with an IC_{50} of <3 nM. RBN012759 displays 300-fold selectivity over the monoPARPs and 1000-fold selectivity over the polyPARPs.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RK-287107

Cat. No.: HY-123892

RK-287107 is a potent and specific **tankyrase** inhibitor with IC_{50}s of 14.3 and 10.6 nM for **tankyrase-1** and **tankyrase-2**, respectively. RK-287107 blocks colorectal cancer cell growth.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Rucaparib

(AG014699; PF-01367338)

Cat. No.: HY-10617A

Rucaparib (AG014699) is an orally active, potent inhibitor of **PARP** proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib is a modest **hexose-6-phosphate dehydrogenase (H6PD)** inhibitor.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Rucaparib monocamsylate

(AG014699 monocamsylate; PF-01367338 monocamsylate)

Cat. No.: HY-102003

Rucaparib (AG014699) monocamsylate is an orally active, potent inhibitor of **PARP** proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib monocamsylate is a modest **hexose-6-phosphate dehydrogenase (H6PD)** inhibitor.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Rucaparib phosphate

(AG-014699 phosphate; PF-01367338 phosphate)

Cat. No.: HY-10617

Rucaparib (AG014699) phosphate is an orally active, potent inhibitor of **PARP** proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib phosphate is a modest **hexose-6-phosphate dehydrogenase (H6PD)** inhibitor.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Senaparib

(IMP4297)

Cat. No.: HY-137450

Senaparib (IMP4297) is a highly potent, selective and orally active **PARP1/2** inhibitor. Senaparib (IMP4297) exhibits strong antitumor activity in animal models.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Talazoparib

(BMN-673; LT-673) Cat. No.: HY-16106

Talazoparib (BMN-673) is a highly potent, orally active **PARP1/2** inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with K_is of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Talazoparib tosylate

(BMN 673ts) Cat. No.: HY-108413

Talazoparib tosylate (BMN 673ts) is a novel, potent and orally available **PARP1/2** inhibitor with an IC_{50} of 0.57 nM for PARP1.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Tankyrase-IN-2

Cat. No.: HY-126248

Tankyrase-IN-2 (compound 5k) is a potent, selective, and orally active **tankyrase** inhibitor (IC_{50}s of 10, 7, and 710 nM for TNKS1, TNKS2 as well as PARP1, respectively).



Purity: 99.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TC-E 5001

Cat. No.: HY-108516

TC-E 5001 is an inhibitor of **Wnt pathway** that inhibits **tankyrase 1/2 (TNKS1/2)** via novel adenosine pocket binding, with K_ds of 79 nM and 28 nM, respectively. TC-E 5001 also inhibits **Axin2** and **STF**, with IC_{50}s of 0.709 μM and 0.215 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UPF 1069

Cat. No.: HY-14478

UPF 1069 is a **PARP** inhibitor, with IC_{50}s of 8 and 0.3 μM for PARP-1 and PARP-2, respectively.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Veliparib

(ABT-888) Cat. No.: HY-10129

Veliparib (ABT-888) is a potent **PARP** inhibitor, inhibiting **PARP1** and **PARP2** with K_is of 5.2 and 2.9 nM, respectively.



Purity: 99.78%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Veliparib dihydrochloride

(ABT-888 dihydrochloride) Cat. No.: HY-10130

Veliparib (dihydrochloride) is a potent inhibitor of **PARP1** a nd **PARP2** with K_is of 5.2 nM and 2.9 nM in cell-free assays, respectively.



Purity: 99.96%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Venadaparib

(IDX-1197) Cat. No.: HY-137457

Venadaparib (IDX-1197) is a potent, selective and orally active **PARP** inhibitor with IC_{50}s of 1.4 nM and 1.0 nM for **PARP1** and **PARP2**, respectively. Venadaparib does not sensitive to PARP-5.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Venadaparib hydrochloride

(IDX-1197 hydrochloride) Cat. No.: HY-137457A

Venadaparib (IDX-1197) hydrochloride is a potent and selective **PARP** inhibitor with anticancer activities. Venadaparib hydrochloride can be used for solid tumors research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Verminoside

Cat. No.: HY-N1094

Verminoside is an iridoid isolated from Kigelia africana, exhibits anti-inflammatory and remarkable antioxidant activity with a radical-scavenging activity of 2.5 μg/mL. The genotoxicity of Verminoside on human lymphocytes is associated with elevated levels of **PARP-1** and **p53** proteins.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

WD2000-012547

Cat. No.: HY-U00223

WD2000-012547 is a selective poly(ADP-ribose)-polymerase (PARP-1) inhibitor with a pK_i of 8.221.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WIKI4

Cat. No.: HY-16910

WIKI4 is a potent **tankyrase** inhibitor with an **IC_{50}** of 26 nM for **TNKS2**. WIKI4 potently inhibits **Wnt/β-catenin** signaling and that its half-maximal response dose is 75 nM.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

XAV-939

Cat. No.: HY-15147

XAV-939 is a potent **tankyrase** inhibitor that targets **Wnt/β-catenin signaling**. XAV-939 stabilizes axin by inhibiting **tankyrase 1** and **tankyrase 2** (**IC_{50}**s of 5 and 2 nM, respectively), thereby stimulating β-catenin degradation.



Purity: 98.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg